Top

Published in:

01-07-2021 | COVID-19

Highlights from the American society of hematology conference 2020

Authors: Punita Grover, Shuchi Gulati

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2021

Abstract

American Society of Hematology conducts an annual meeting, where investigators from around the globe presented ground-breaking research in the fields of malignant and non-malignant hematology. We provide a summary of non-malignant hematology abstracts from the 2020 meeting. Topics included range from those related to thrombosis, including thrombotic complications of COVID-19, bleeding and novel therapies such as gene therapies. Readers are encouraged to access meeting materials for a more detailed coverage of the event.

Davenport A (2011) What are the anticoagulation options for intermittent hemodialysis? Nat Rev Nephrol 7(9):499–508CrossRefPubMed

Lorentz CU, Verbout NG, Shatzel JJ et al (2020) Safety and efficacy of the contact activation inhibitor AB023 in patients with end-stage renal disease on chronic hemodialysis: A phase 2, double-blind, randomized placebo-controlled trial. Blood 136(Supplement 1):23–24CrossRef

Khorana AA, Kuderer NM, Culakova E et al (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902–4907CrossRefPubMedPubMedCentral

Iorio A, Kearon C, Filippucci E et al (2010) Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 170(19):1710–1716CrossRefPubMed

Kapoor S, Opneja A, Gollamudi J et al (2020) Prior history of venous thromboembolism is a significant risk factor for recurrence of thrombosis after cancer diagnosis. Blood 136(Supplement 1):32–33CrossRef

Eichinger S, Hron G, Bialonczyk C et al (2008) Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med 168(15):1678–1683CrossRefPubMed

McCaughan GJ, Crowther HJ, Chen V et al (2020) Australian and New Zealand registry of anticoagulation in the obese: prescribing patterns, drug levels and patient outcomes. Blood 136(Supplement 1):21–21CrossRef

Hart RG, Diener HC, Yang S et al (2012) Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 43(6):1511–1517CrossRefPubMed

Hankey GJ, Stevens SR, Piccini JP et al (2014) Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke 45(5):1304–1312CrossRefPubMed

10.

Srinathan S, Cipkar C, Chiang P et al (2020) Mortality rate and functional outcomes among patients presenting with anticoagulation- associated intracranial hemorrhage. Blood 136(Supplement 1):24–25CrossRef

11.

Inohara T, Xian Y, Liang L et al (2018) Association of intracerebral hemorrhage among patients taking non-vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital mortality. JAMA 319(5):463–473CrossRefPubMedPubMedCentral

12.

Tsivgoulis G, Katsanos AH, Seiffge DJ et al (2020) Fatal intracranial haemorrhage occurring after oral anticoagulant treatment initiation for secondary stroke prevention in patients with atrial fibrillation. Eur J Neurol 27(8):1612–1617CrossRefPubMed

13.

Ansell J, Laulicht B, Bakhru S et al (2020) Reversal of anticoagulation by ciraparantag: time to onset and duration of effect. Blood 136(Supplement 1):24–24CrossRef

14.

Loo J, Spittle DA, Newnham M (2021) COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax 76(4):412–420CrossRefPubMed

15.

Poissy J, Goutay J, Caplan M et al (2020) Pulmonary embolism in patients with COVID-19. Circulation 142(2):184–186CrossRefPubMed

16.

Malas MB, Naazie IN, Elsayed N et al (2020) Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2020.100639CrossRefPubMedPubMedCentral

17.

Nopp S, Moik F, Jilma B et al (2020) Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Res Pract Thromb Haemost 4(7):1178–1191CrossRefPubMedCentral

18.

Goshua G, Liu Y, Meizlish ML et al (2020) Admission Rothman index, aspirin, and intermediate dose anticoagulation effects on outcomes in COVID-19: a multi-site propensity matched analysis. Blood 136(Supplement 1):23–24CrossRef

19.

Al-Samkari H, Gupta S, Karp Leaf R et al (2020). Thrombosis, bleeding, and the effect of anticoagulation on survival in critically ill patients with COVID-19 in the United States [abstract]. American Society of Hematology Annual Meeting

20.

Patell R, Bogue T, Koshy A et al (2020) Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood 136(11):1342–1346CrossRefPubMed

21.

Roberts LN, Whyte MB, Georgiou L et al (2020) Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood 136(11):1347–1350CrossRefPubMed

22.

Giannis D, Allen SL, Davidson A et al (2020) Thromboembolic outcomes of hospitalized COVID-19 patients in the 90-day post-discharge period: early data from the northwell CORE-19 registry. Blood 136(Supplement 1):33–34CrossRef

23.

Bhalla V, Lamping OF, Abdel-Latif A et al (2020) Contemporary meta-analysis of extended direct-acting oral anticoagulant thromboprophylaxis to prevent venous thromboembolis. Am J Med 133(9):1074-1081.e1078CrossRefPubMed

24.

Eswaran H, Jarmul J, Shaheen A et al (2020) Incidence of vascular thromboembolic events in outpatients with mild COVID-19. Blood 136(Supplement 1):31–32CrossRef

25.

Li A, Kuderer NM, Warner JL et al (2020) Incidence of and risk factors for venous thromboembolism among hospitalized patients with cancer and COVID-19: report from the COVID-19 and cancer consortium (CCC19) registry. Blood 136(Supplement 1):56–58CrossRef

26.

Gernsheimer TB, Brown SP, Triulzi DJ et al (2020) Effects of tranexamic acid prophylaxis on bleeding outcomes in hematologic malignancy: the a-TREAT trial. Blood 136(Supplement 1):1–2CrossRef

27.

Neunert C, Noroozi N, Norman G et al (2015) Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost 13(3):457–464CrossRefPubMedPubMedCentral

28.

Bradbury CA, Greenwood R, Pell J et al (2020) A multicentre randomised trial of first line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The flight trial. Blood 136(Supplement 2):LBA-2CrossRef

29.

Kuter DJ, Efraim M, Mayer J et al (2020) Oral rilzabrutinib, a bruton tyrosine kinase inhibitor, showed clinically active and durable platelet responses and was well-tolerated in patients with heavily pretreated immune thrombocytopenia. Blood 136(Supplement 1):13–14

30.

Frangoul H, Altshuler D, Cappellini MD et al (2020) CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med 384(3):252–260CrossRefPubMed

31.

Frangoul H, Bobruff Y, Cappellini MD et al (2020) Safety and efficacy of CTX001 in patients with transfusion-dependent β-thalassemia and sickle cell disease: early results from the climb THAL-111 and climb SCD-121 studies of autologous CRISPR-CAS9-modified CD34+ hematopoietic stem and progenitor cells. Blood 136(Supplement 1):3–4CrossRef

32.

Pipe SW, Recht M, Key NS et al (2020) First data from the phase 3 HOPE-B gene therapy trial: efficacy and safety of etranacogene dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in adults with severe or moderate-severe hemophilia B treated irrespective of pre-existing anti-capsid neutralizing antibodies. Blood 136(Supplement 2):LBA-6CrossRef

Title: Highlights from the American society of hematology conference 2020
Authors: Punita Grover
Shuchi Gulati
Publication date: 01-07-2021
Publisher: Springer US
Keywords: COVID-19
Thrombosis
Idiopathic Thrombocytopenic Purpura
Hematology
Published in: Journal of Thrombosis and Thrombolysis / Issue 1/2021
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-021-02449-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Highlights from the American society of hematology conference 2020

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Small lipid core burden index in patients with stable angina pectoris is also associated with microvascular dysfunction: Insights from intracoronary electrocardiogram

Elderly people are inherently sensitive to the pharmacological activity of rivaroxaban: implications for DOAC prescribing

Acute pulmonary embolism following recent hospitalization or surgery

Assessment of provider practices regarding venous thromboembolism management and prevention in pediatric acute leukemia patients

Clinical and sociodemographic factors associated with anticoagulant use for cancer associated venous thromboembolism

Bivalirudin dosing during prolonged intermittent renal replacement therapy: a case report

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page